Liver Cancer Center

Clinical trials are imperative to cancer research and treatment. Our physician-scientists are committed to conducting studies to help answer the disease's most pressing and potentially life-saving questions.

The Liver Cancer Center is proud to currently lead the world's largest hepatocellular carcinoma (HCC) prevention study. This study will follow thousands of patients world-wide whom possess known liver cancer risk factors. Participants are followed over time to help experts understand who is most at risk and identify which risk factors have the greatest effect on disease development and prognosis. The study will also help establish the best ways to screen patients and, if diagnosed, the most effective treatment.

This revolutionary study is a cornerstone of the Liver Cancer Center. To learn more about this study, please call 617-632-4500.

Current liver cancer clinical trials enrolling patients include:

• A Phase 1 Open-label Dose Escalation and Dose Expansion Study of CGX1321 in Subjects with Advanced Solid Tumors and Phase 1b Study of CGX1321 in Combination with Pembrolizumab in Subjects with Advanced Gastrointestinal Tumors.
  
  The purpose of the Dose Escalation Phase is to examine the safety and determine the maximum tolerated dose of CGX1321 when administered to subjects with advanced solid tumors.
  
  The purpose of the Dose Expansion Phase, Roll-over Cohort and Phase 1b is to continue to examine the safety and confirm the final Phase 2 dose of CGX1321 alone in subjects with advanced GI tumors (Dose Expansion Phase) and evaluate the safety and tolerability of CGX1321 in combination with pembrolizumab (Phase 1b and Roll-over Cohort)

See a complete list of our current liver cancer clinical trials (enter "liver cancer" in the search bar).